Future Fields is a Canadian CDMO specializing in recombinant protein production using its proprietary EntoEngine platform based on Drosophila melanogaster (fruit flies). The company offers custom protein expression services for difficult-to-express proteins, serving biopharma, agriculture, and food innovation clients. Future Fields operates a 6,000 sq ft production facility (Instar 1.0) and has raised $8 million in Series A funding.
Recombinant protein production, EntoEngine insect-based expression platform, difficult-to-express proteins, custom protein services, Drosophila melanogaster expression
1 site worldwide
No certifications on file yet.
No reviews available yet.
No documents available.